Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4195 EUR | +0.36% | +2.32% | -8.80% |
04-05 | GenSight: financial visibility assured until the end of April | CF |
03-25 | GenSight: share price falls, limited financial visibility | CF |
Sales 2024 * | 4.4M 4.7M 377M | Sales 2025 * | 7.4M 7.91M 634M | Capitalization | 32.73M 35M 2.8B |
---|---|---|---|---|---|
Net income 2024 * | -26M -27.8M -2.23B | Net income 2025 * | -25M -26.73M -2.14B | EV / Sales 2024 * | 20.6 x |
Net Debt 2024 * | 57.8M 61.8M 4.95B | Net Debt 2025 * | 85.7M 91.63M 7.34B | EV / Sales 2025 * | 16 x |
P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.75
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.4% |
Latest transcript on GenSight Biologics S.A.
1 day | +0.36% | ||
1 week | +2.32% | ||
Current month | +4.35% | ||
1 month | +4.88% | ||
3 months | +2.94% | ||
6 months | -31.12% | ||
Current year | -8.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 18/05/21 | |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/22 |
Magali Taiel
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 30/09/13 |
Cédric Moreau
BRD | Director/Board Member | 37 | 10/06/19 |
Maritza McIntyre
BRD | Director/Board Member | 58 | 10/06/19 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.4195 | +0.36% | 10,572 |
25/04/24 | 0.418 | +0.97% | 23,048 |
24/04/24 | 0.414 | +1.72% | 31,346 |
23/04/24 | 0.407 | -0.61% | 2,959 |
22/04/24 | 0.4095 | -0.12% | 26,841 |
Real-time Euronext Paris, April 26, 2024 at 03:03 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.80% | 34.94M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SIGHT Stock